In cancer treatment, angiogenesis can be inhibited by bevacizumab, a monoclonal antibody that targets VEGF, preventing the signaling pathway that results in the proliferation and migration of endothelial cells; however, HIF-1α may contribute to bevacizumab resistance. This evidence concerns the gene HIF1A and cancer.